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duration was analyzed using Kaplan Meier estimates.
Statistical comparison of the survival curves was done
with the Log-rank test. We pooled IMS Mediplus data
(patient medical records completed by general practitio-
ners) from Germany, France and the United Kingdom for
analysis. Data was obtained for all irbesartan patients
with at least one year of follow-up and from randomly
selected samples of patients treated with either diuretics,
beta blockers, calcium channel blockers, ACE inhibitors,
or other AIIRA. Patients were newly diagnosed with hy-
pertension between October 1, 1997 and November 30,
1998 and initiated antihypertensive treatment as mono-
therapy.
RESULTS: Patients included (2,416) were initiated on di-
uretics (422), beta blockers (441), calcium channel block-
ers (466), ACE inhibitors (333), losartan (188), irbe-
sartan (380), other AIIRA (186). When irbesartan was
prescribed, more patients remained on that therapy
(60.8%) than with all other antihypertensives (44.2%, p 
0.001), or other AIIRAs (51.3%, p  0.009). Compared
to patients taking all other antihypertensives, fewer pa-
tients receiving irbesartan required adjunctive therapy
(16.1% vs 25.3%, p  0.001) or switched therapy (9.0%
vs 13.6%, p  0.013).
CONCLUSIONS: Irbesartan was superior compared to
all antihypertensives in achieving persistence of initial
therapy. By evaluating persistence rather than compli-
ance, we captured both the patient’s and the physician’s
role in determining the course of treatment.
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OBJECTIVE: Controlled clinical trials have demon-
strated the positive impact of statin therapy on health
outcomes in hyperlipidemic patients. The positive impact
of adherence is seemingly intuitive and many programs
have been designed to improve adherence. However,
there are few studies analyzing the cost-effectiveness of
medication-adherence interventions. This decision analy-
sis model will examine the cost-effectiveness of programs
designed to enhance medication adherence in patients
taking statins. The model varies the medication-adher-
ence rate and program costs to determine the differences
in the expected outcome of three different types of inter-
vention.
METHODS: Data from published clinical and pharma-
coeconomic studies were entered into a decision analysis
model. A Monte Carlo simulation using 10,000 trials
was used with beta distributions for the assumptive vari-
ables. The baseline adherence rate was set at 67% and
the cardiovascular event rate at 1.5%. Behavioral (B)
type interventions were assumed to increase adherence by
8.61%, Educational (E) interventions by 11.22% and
Combined (C) B and E by 17.04%. Program costs were
estimated as follows: B  $200, E  $100, and C 
$225 per patient. Cardiovascular and serious medication-
related events were also used as outcomes. The cost-per-
patient-per-event avoided was calculated. ANOVA was
used to test for differences among intervention types.
RESULTS: The results showed that the interventions in-
creased the number of events avoided in the first year by
0.04 (95% CI  0.04,0.12) for B, by 0.06 (95%CI 
0.02, 0.14) for E and by 0.08 (95%CI  0.02, 0.14)
for C. The cost-per-event-per-patient avoided in the first
year of treatment was B  $6,038, E  $2,568 and C 
$3,839. There was a statistical difference among all inter-
vention types with respect to cost of events avoided.
CONCLUSIONS: There was no difference in the number
of events avoided in the first year of statin treatment with
respect to intervention type. While C interventions yielded
more events avoided, E interventions appear to be the
most cost-effective. More study on the cost-effectiveness
of medication adherence programs is required.
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Patients with heart failure suffer from poor health out-
comes due to multiple co-morbidity requiring multiple
medications. Patients who misunderstand their diagnosis
and treatment plan may use their medication subopti-
mally. Providing knowledge through education is one
mechanism that can help patients improve medication
compliance.
OBJECTIVES: To develop and establish measurement
properties of two distinct instruments that can be used in
patients with heart failure (HF) to measure acceptability
of educational materials and subsequent knowledge
gained following an educational intervention.
METHODS: Using an expert panel, we developed mini-
mal criteria required to educate patients with HF. Subse-
quently, we developed and tested two questionnaires.
The first measure, which we refer to as a measure of edu-
cational material acceptability (EMA) was developed to
help us differentiate between booklets designed to edu-
cate patients with HF so as to select which booklets were
most acceptable to the patient. The second measure,
which we refer to as the measure of knowledge acquisi-
tion (MKA), was developed to help us evaluate the im-
pact of our educational intervention on knowledge. MKA
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questionnaires were administered pre- and post-interven-
tion to 126 heart-failure patients within a randomized
controlled trial at a university-affiliated teaching center
with a referral base of HF patients.
RESULTS: The internal consistency of the EMA was
0.79 (Cronbach’s alpha). The internal consistency of the
MKA was 0.61 and the responsiveness was 0.75.
CONCLUSIONS: The availability of instruments, such
as those we have developed, can assist heart-failure pro-
grams to evaluate the impact of their educational inter-
ventions on knowledge gained, which will hopefully
translate into better patient outcomes.
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OBJECTIVE: Joint National Committee on Detection,
Evaluation, and Treatment of High Blood Pressure V
(1993) and VI (1997) recommend diuretics and beta-
blockers as initial antihypertensive drugs. However, a
few studies have shown a trend of increasing use of an-
giotensin-converting enzyme inhibitors (ACEIs) and cal-
cium channel blockers (CCBs), and decreasing use of di-
uretics and beta-blockers. The purpose of the study was
to examine the impact of insurance types on patterns of
antihypertensive drug use.
METHODS: A logistic regression model was employed
to examine whether insurance type was associated with
patterns of antihypertensive drug use by using Medical
Expenditure Panel Survey (MEPS, 1996), after control-
ling for confounding variables. The estimated study pop-
ulation enrolled was 10,357,769 non-institutionalized
adult US patients with essential hypertension.
RESULTS: Patients with HMO insurance were less likely
to use diuretics or beta-blockers (OR  0.499, 95%CI:
0.323-0.770), compared with the patients with fee-for-
service (FFS) insurance. Black patients were less likely to
use diuretics or beta-blockers compared with white pa-
tients (OR  0.577, 95%CI: 0.346-0.961). Compared
with non-married patients, married patients were 92 per-
cent more likely to use diuretics or beta-blockers (OR 
1.92, 95%CI: 1.299-2.838). Finally, patients diagnosed
between 1988 and 1992, and after 1993 were less likely
to use diuretics or beta-blockers (OR  0.486, 95%CI:
0.289-0.817; OR  0.416, 95%CI: 0.251-0.691), com-
pared with patients who were diagnosed with hyperten-
sion before 1988.
CONCLUSION: Insurance types are associated with the
patterns of antihypertensive drug use. Patients with
HMO insurance used more ACEIs or CCBs than patients
with FFS insurance. Further research is required to dis-
cern the reasons for the impact of insurance types so that
policy makers can propose efficient intervention.
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Pharmacists, as easily accessible health-care professionals
and advisors to the general public, are distributors of in-
formation and dispensers of health-care products. The
“French Consensus Conference on Smoking Cessation” –
(October 1998), summed up the aims of pharmacists in
helping smoking cessation as follows: lead by example;
enforce smoking bans in pharmacies; underline the signif-
icant risks linked to cigarette smoking; encourage non
smoking; advise, aid and monitor the smoker who has
decided to stop smoking.
OBJECTIVE: To measure the progress of the French
Pharmacist’s Smoking Cessation Program.
METHODS: The STOP program, through a question-
naire distributed to approximately 2500 pharmacists,
aims at describing the progress pharmacists are making
with regard to their own tobacco dependence as well as
in the public health initiative entrusted to them.
RESULTS: Here we present the preliminary results of
this investigation, through the analysis of the first 300
questionnaires. The average age of our sample popula-
tion was 46 years, 55 % were male. 67% had attended a
smoking cessation course. Ninety percent of these at-
tended a course given by the pharmaceutical industry,
and 7% attended a course given by an anti-smoking or-
ganization. Ninety eight percent of the pharmacists that
replied offered information on aiding smoking cessation,
either through window displays(67%) or displays in the
pharmacy (70 %). After delivering a nicotine substitute,
80% of pharmacists do not arrange a follow-up appoint-
ment. This lack of follow-up is explained on the part of
the client by lack of motivation (48%) and clients not re-
turning to the same pharmacy (34%). For the pharmacist
the main reason is the absence of adequate follow-up
tools (54%).
CONCLUSION: Since the delisting of nicotine substi-
tutes, pharmacists have played a major role in their deliv-
ery and should therefore play a strategic role in the fight
against tobacco dependence.
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